

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 9, 2026

InVivoMab anti-mouse PD-L1 (B7-H1)

RRID:AB_10949073

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0101, RRID:AB_10949073)

Antibody Information

URL: http://antibodyregistry.org/AB_10949073

Proper Citation: (Bio X Cell Cat# BE0101, RRID:AB_10949073)

Target Antigen: PD-L1 (B7-H1)

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow Cytometry, Immunofluorescence, Immunohistochemistry, in vivo Neutralization & Blocking, Western Blot, in vitro Organoids/Organ-on-Chip
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:TRUE

Antibody Name: InVivoMab anti-mouse PD-L1 (B7-H1)

Description: This monoclonal targets PD-L1 (B7-H1)

Target Organism: mouse

Clone ID: clone 10F.9G2™

Antibody ID: AB_10949073

Vendor: Bio X Cell

Catalog Number: BE0101

Alternative Catalog Numbers: BE0101-100MG, BE0101-25MG, BE0101-50MG, BE0101-1MG, BE0101-5MG

Record Creation Time: 20260114T193156+0000

Record Last Update: 20260706T190413+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:TRUE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for InVivoMab anti-mouse PD-L1 (B7-H1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 183 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Jana S, et al. (2026) Collagen-Bearing Exosomes from Breast Cancer-Associated Fibroblasts Promote T-cell Dysfunction. Cancer research communications, 6(3), 630.

Deng Z, et al. (2026) Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity. Cancer research, 86(11), 2793.

Karakousi T, et al. (2026) IFN γ -dependent metabolic reprogramming restrains an immature, pro-metastatic lymphatic state in melanoma. Cancer cell, 44(4), 792.

Hammons JN, et al. (2026) Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma. Hepatology (Baltimore, Md.), 84(1), 20.

Frank K, et al. (2026) PD-L1 is an intrinsic switch for natural killer cell-mediated, TRAIL-dependent antiviral function. Cell reports, 45(2), 116939.

Yang Y, et al. (2026) Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8 $^{+}$ T cells. Journal for immunotherapy of cancer, 14(3).

Xue H, et al. (2026) UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD-L1 Transcription. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e76223.

Hu Z, et al. (2026) Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. *Immunity*, 59(7), 1928.

Zhang M, et al. (2026) Microglia prune developing cortical blood vessels through PD-1 signaling. *Nature neuroscience*.

Guo W, et al. (2026) Tumor-initiating stem cells fine-tune the plasticity of neutrophils to sculpt a protective niche. *Cancer cell*, 44(1), 94.

Chen M, et al. (2026) Nano-granulated zoledronate sensitizes innate immune metabolism to enhance vaccine-induced and antitumor immunity. *Cell reports. Medicine*, 7(5), 102765.

Ghaffari S, et al. (2026) A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. *iScience*, 29(5), 115669.

Pei S, et al. (2026) Neutrophil regulation of immunotherapy for cancer is controlled by type II interferon. *Immunity*, 59(7), 1982.

Morosan S, et al. (2026) Opposing Association of Lung Neutrophils and PD-L1+ Monocytes in Age-Related Severity of SARS-CoV-2 Infection. *Aging cell*, 25(6), e70588.

Qian J, et al. (2026) Disease-associated microglia adopt stage-specific phenotypes that regulate T cell fate and immunity in glioma. *Immunity*.

Zhang H, et al. (2026) Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors. *Cell reports. Medicine*, 7(2), 102545.

Wang XX, et al. (2026) Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer. *Journal for immunotherapy of cancer*, 14(2).

Zhang T, et al. (2026) Chemically Engineered *L. reuteri* Delivering ?PD-L1 and Gallium Ions via Metal-Phenolic Networks Potentiate Anti-Tumor Immunity and Ferroptosis. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(31), e21638.

Zhang Q, et al. (2026) Druggable ?-catenin palmitoyl-switch coordinates immune evasion via immunogenic ferroptosis resistance and PD-L1-mediated immunosuppression. *Cell reports. Medicine*, 7(6), 102837.

Zhao Y, et al. (2026) An immunogenomic classification of solid tumours reveals subtype-specific therapeutic vulnerabilities for immunotherapy. *EBioMedicine*, 129, 106323.